Available Trials
Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.
If you are interested in learning more about our research program, please call the VOA Research Department in the area closest to you:
Peninsula: (757) 873-9400
- Hampton
- Newport News
- Williamsburg
Southside: (757) 466-8683
- Norfolk
- Virginia Beach
Breast Cancer Research
-
MERCK KEYLYNK MK7339-009
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)
Available at 3 locations
-
USO 18282
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) In Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens (IMMU-132-09)
Available at 1 location
-
USO 17026
A Phase II, Multicenter, Open-Label, Three-Cohort, Noncomparative Study To Assess The Efficacy And Safety Of Alpelisib Plus Fulvestrant Or Letrozole In Patients With PIK3CA Mutant,Hormone Receptor (HR) Positive, HER2-Negative Advanced Breast Cancer (Abc), Who Have Progressed On Or After Prior Treatments (CBYL719X2402)
Available at 1 location
-
USO 19009
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)
Available at 3 locations
-
USO 18232
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)
Available at 1 location
-
USO 17188
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)
Available at 5 locations
-
Alliance A011502 (ABC Trial)
A Randomized Phase III Double Blinded Placebo-Controlled Trial Of Aspirin As Adjuvant Therapy For Node-Positive, HER2 Negative Breast Cancer
Available at 6 locations
GYN Cancer Research
-
USO 20225
A Phase 2, Multicenter, Single-Arm, Open-Label Study To Evaluate The Efficacy And Safety Of AK104 In Subjects With Recurrent Or Metastatic Cervical Cancer (AK104-201-AU) STAR
Available at 3 locations
-
USO 19221
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Pa;clitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (D9311C00001;GOG-3041; ENGOT-EN10)
Available at 2 locations
-
USO 18269
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer ( ENGOT-ov50 / INNOVATE-3)
Available at 1 location
-
USO 17218
A Randomized, Double-Blind, Phase 3 Comparison Of Platinum-Based Therapy With TSR-042 And Niraparib Versus Standard Of Care Platinum-Based Therapy As First-Line Treatment Of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44)
Available at 5 locations
-
USO 18232
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)
Available at 1 location
-
USO 17182
Clovis A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ClovisCO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA)
Available at 3 locations
Genitourinary Cancer Research
-
PSMA 302
PSMA 302: A Prospective, Phase 3, Multi-Center, Single-Arm, Imaging Study Investigating The Safety And Diagnostic Performance Of Rhpsma-7.3 (18F) PET Ligand In Men With Suspected Prostate Cancer Recurrence Based On Elevated PSA Following Prior Therapy.
Available at 3 locations
-
PSMA 301
PSMA 301: A prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating The Safety And Diagnostic Performance Of rhPSMA 7.3 (18F) PET Ligand In Men With Newly Diagnosed Prostate Cancer
Available at 3 locations
-
USO 19094
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302) (QBGJ398-302)
Available at 1 location
-
USO 17133
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) (42756493BLC3001)
Available at 1 location
-
USO 19032
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)
Available at 2 locations
-
USO 18095
A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)
Available at 5 locations
-
JANSSEN 56021927PCR2032
JANSSEN 56021927PCR2032: An Open-label, Multicenter, Phase Ib Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer
Available at 1 location
-
USO 17165
Phase 1b/2 Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations (42756493BLC2002)
Available at 1 location
-
Duke Panther Pro00075097
Duke Panther Pro00075097: Prospective Study of Apalutamide and Abiraterone Acetate In Chemo Therapy Naïve Men with mCRPC Stratified by Race (Pro00075097)
Available at 2 locations
Hematology
-
USO 18177
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) (ASTX727-03)
Available at 1 location
Leukemia & Lymphoma Research
-
USO 18281
A Phase 1a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas (APTO-CG-806-01)
Available at 1 location
-
USO 18104
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (017007)
Available at 1 location
Lung Cancer Research
-
USO 20137
A Phase III, Open-Label, Randomized Study Of Atezolizumab And Tiragolumab Compared With Durvalumab In Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (GO41854)
Available at 5 locations
-
USO 19143
A Phase 3 Multicenter, Randomized, Open Label, Active-Controlled, Study Of AMG 510 Versus Docetaxel For The Treatment Of Previously Treated Locally Advanced And Unresectable Or Metastatic NSCLC Subjects With Mutated KRAS P.G12C (20190009)
Available at 5 locations
-
USO 19209
USO 19209: A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC) (20190294)
Available at 5 locations
-
USO 19109
A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (Fl) (C2321001)
Available at 1 location
-
USO 18234
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer (AB928CSP0004)
Available at 1 location
Multiple Myeloma
-
USO 19247
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Available at 5 locations
Solid Tumors Research
-
USO 19151
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR
Available at 1 location
-
USO 19079
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) (INCB 54828-207)
Available at 2 locations
-
LOXO-EXT-17005
LOXO-EXT-17005: Phase 1/2 Study Of The TRK Inhibitor LOXO-195 In Adult And Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Available at 1 location
-
Ignyta (RXDX 101-02)
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Available at 1 location